Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

Opens in a new tab or window Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose.

Tirzepatide targets two receptors in order to shrink fat cells and reduce the impacts that enlarged fat cells have on heart and kidney health. The drug is approved by the U.S. Food and Drug ...

The Indian pharmaceutical market (IPM) grew by 8.4 per cent in the financial year (FY) 2025 on the back of major therapies ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c ...

The clinical benefits of tirzepatide in patients with HFpEF and obesity were consistent regardless of kidney function. The effect of tirzepatide on kidney function depends on how CKD is defined ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. HealthDay News — For patients with inadequately controlled type 2 diabetes ...

Both are chronic conditions that progressively worsen over time. Tirzepatide targets two receptors in order to shrink fat cells and reduce the impacts that enlarged fat cells have on heart and ...

At week 40, HbA1c decreased by 1.44% with tirzepatide versus 0.67% with dulaglutide, and weight loss was 10.5 kg versus 3.6 kg, respectively. Both treatments had similar rates of serious adverse ...

Previous studies have shown improved kidney function with other drugs in the same class but this trial is the first to assess tirzepatide's impact on kidney and cardiovascular outcomes in people ...